Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SP600125 (JNK Inhibitor II) 是一种 JNK 抑制剂,抑制 JNK1、JNK2 和 JNK3 (IC50=40/40/90 nM),具有口服有效性、可逆性和 ATP 竞争性。SP600125 可以抑制自噬,诱导凋亡。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 449 | 现货 | ||
50 mg | ¥ 712 | 现货 | ||
100 mg | ¥ 996 | 现货 | ||
200 mg | ¥ 1,885 | 现货 | ||
500 mg | ¥ 3,997 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 321 | 现货 |
产品描述 | SP600125 (JNK Inhibitor II) is a JNK inhibitor that inhibits JNK1, JNK2, and JNK3 (IC50=40/40/90 nM) with oral potency, reversibility, and ATP-competitive properties. SP600125 inhibits autophagy and induces apoptosis. |
靶点活性 | JNK3:90 nM (cell free), JNK1:40 nM (cell free), JNK2:40 nM (cell free) |
体外活性 |
方法:小鼠肺癌细胞 LLC 和小鼠肿瘤细胞 4T1 用 SP600125 (3-10 μM) 处理 72 h,使用 MTT assay 检测细胞活力。 结果:SP600125 剂量依赖性抑制 LLC 和 4T1 细胞生长,IC50 为 8.14 μM 和 7.37 μM。[1] 方法:Jurkat T 细胞 用 SP600125 (1-50 μM) 预处理 10 min,随后用 PMA (50 ng/mL)、anti-CD3 (0.5 μg/mL) 和 anti-CD28 (2 μg/mL) 刺激 30 min,使用 Western Blot 方法检测靶点蛋白表达水平。 结果:SP600125 以 5-10 μM 的 IC50 阻断 c-Jun 的磷酸化。在 50 μM 的浓度下,SP600125 不阻断 ERK 的磷酸化,也不抑制 IκBα 的降解。在 50 μM 时观察到 磷酸-p38 和 ATF2 的部分抑制,但在 25 μM 时没有观察到。[2] |
体内活性 |
方法:为检测体内对 TNF-α 的抑制活性,将 SP600125 (7.5-30 mg/kg,30% PEG-400/20% polypropylene glycol/15% Cremophor EL/5% ethanol/30% saline) 静脉注射或口服给药给 CD-1 小鼠,15 min 后注射 LPS 诱导的 TNF-α 表达。 结果:静脉注射 15 或 30 mg/kg SP600125 可显著抑制 TNF-α 血清水平,而口服给药剂量依赖性阻断 TNF-α 表达,每次口服 30 mg/kg 可观察到显著抑制作用。[2] 方法:为检测体内抗肿瘤活性,将 SP600125 (5 mg/kg) 和 C-2 (10 mg/kg) 腹腔注射给携带膀胱癌肿瘤 BIU87 的 nude 小鼠,每天一次,持续二十一天。 结果:C-2 治疗抑制了肿瘤的生长,C-2/SP600125 组肿瘤显著低于用载体或 C-2 单独治疗的小鼠。[3] |
细胞实验 | Multiarray plate screening of mRNA was performed by High Throughput Genomics. In brief, cell lysates were prepared by using a single-step proprietary lysis buffer. Lysates were incubated with a 16-gene capture array manufactured into each well of a 96-well plate. Detection was by luminescence and was performed by HTG. SDs for triplicate samples were typically 3–8% for samples with high levels of gene expression and 15–25% for samples with very low (near-threshold) levels of cytokine gene expression [1]. |
动物实验 | Mouse LPS/TNF assay was performed as follows: Female CD-1 mice (8–10 weeks of age) were dosed i.v. or per os with SP600125 in PPCES vehicle (30% PEG-400/20% polypropylene glycol/15% Cremophor EL/5% ethanol/30% saline), final volume of 5 ml/kg, 15 min before i.v. injection with LPS in saline (0.5 mg/kg; Escherichia coli 055:B5). At 90 min, a terminal bleed was obtained from the abdominal vena cava, and the serum was recovered. Samples were analyzed for mouse TNF-α by using an ELISA. The in-life phase of the thymocyte apoptosis assay was performed in female C57BL/6 mice. SP600125 was administered at 0, 12, 24, and 36 h, 15 mg/kg s.c. in PPCES vehicle. Anti-CD3 (50 μg) i.p. (clone 145-2C11) was administered as a single dose immediately after SP600125 at time 0. After 48 h, mice were killed, and the thymus was dissected for thymocyte isolation. Treated and untreated mice thymuses were excised and immediately placed in complete medium (RPMI medium 1640 with 10% FBS, penicillin/streptomycin, and l-glutamine) on ice. Each thymus was then pressed between the frosted ends of 2 microscope slides to form a single cell suspension and collected through a 30 μm nylon mesh. Cells were stained for cell surface CD4 and CD8 and apoptosis and measured by flow cytometry [1]. |
别名 | 1PMV, JNK Inhibitor II, Nsc75890, Pyrazolanthrone |
分子量 | 220.23 |
分子式 | C14H8N2O |
CAS No. | 129-56-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 22 mg/mL (100 mM)
Ethanol: 1.1 mg/mL (5 mM)), with gentle warming
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 4.5407 mL | 22.7035 mL | 45.4071 mL | 113.5177 mL |
5 mM | 0.9081 mL | 4.5407 mL | 9.0814 mL | 22.7035 mL | |
DMSO | 10 mM | 0.4541 mL | 2.2704 mL | 4.5407 mL | 11.3518 mL |
20 mM | 0.227 mL | 1.1352 mL | 2.2704 mL | 5.6759 mL | |
50 mM | 0.0908 mL | 0.4541 mL | 0.9081 mL | 2.2704 mL | |
100 mM | 0.0454 mL | 0.227 mL | 0.4541 mL | 1.1352 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SP600125 129-56-6 Apoptosis Autophagy Cell Cycle/Checkpoint Chromatin/Epigenetic MAPK Tyrosine Kinase/Adaptors Ferroptosis Trk receptor Aurora Kinase JNK ATP-competitive inhibit 1PMV JNK Inhibitor II Inhibitor Nsc75890 Pyrazolanthrone SP-600125 phosphorylation SP 600125 reversible inhibitor